1. A Potential Role of Salmonella Infection in the Onset of Inflammatory Bowel Diseases
    Bárbara M. Schultz et al, 2017, Front. Immunol. CrossRef
  2. Doxycycline, metronidazole and isotretinoin: Do they modify microRNA/mRNA expression profiles and function in murine T-cells?
    Eugenia Becker et al, 2016, Sci Rep CrossRef
  3. null
    Monica I. Ardura et al, 2017 CrossRef
  4. Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease
    Xochitl C Morgan et al, 2015, Genome Biol CrossRef
  5. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
    Giovanni Cammarota et al, 2015, Pharmacology & Therapeutics CrossRef
  6. Gut microbiota and IBD: causation or correlation?
    Josephine Ni et al, 2017, Nat Rev Gastroenterol Hepatol CrossRef
  7. Insights from immunology: New targets for new drugs?
    Tim Raine, 2014, Best Practice & Research Clinical Gastroenterology CrossRef
  8. IBD and the Gut Microbiota—from Bench to Personalized Medicine
    Emanuelle Bellaguarda et al, 2015, Curr Gastroenterol Rep CrossRef
  9. The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood
    John Slattery et al, 2016, Clinical Medicine Insights: Pediatrics CrossRef
  10. Role of antibiotics for treatment of inflammatory bowel disease
    Orna Nitzan, 2016, WJG CrossRef
  11. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management
    J. McIlroy et al, 2017, Aliment Pharmacol Ther CrossRef
  12. PCR detection of segmented filamentous bacteria in the terminal ileum of patients with ulcerative colitis
    Alessia Finotti et al, 2017, BMJ Open Gastroenterol CrossRef
  13. Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy
    Daniela Elena Serban, 2015, Nutr Clin Pract CrossRef
  14. Helminth therapy (worms) for induction of remission in inflammatory bowel disease
    Sushil K Garg et al, 2014 CrossRef
  15. Perturbation of the Human Microbiome as a Contributor to Inflammatory Bowel Disease
    Bayan Missaghi et al, 2014, Pathogens CrossRef
  16. Evidence-based clinical practice guidelines for inflammatory bowel disease
    Katsuyoshi Matsuoka et al, 2018, J Gastroenterol CrossRef
  17. Life-long antimicrobial therapy: where is the evidence?
    Jillian S Y Lau et al, 2018 CrossRef
  18. null
    Wayne Young et al, 2018 CrossRef
  19. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?
    Dana Berg et al, 2015, Expert Review of Gastroenterology & Hepatology CrossRef
  20. Management of Paediatric Ulcerative Colitis, Part 2
    Dan Turner et al, 2018, Journal of Pediatric Gastroenterology and Nutrition CrossRef
  21. Management of Paediatric Ulcerative Colitis, Part 1
    Dan Turner et al, 2018, Journal of Pediatric Gastroenterology and Nutrition CrossRef
  22. The Microbiome in Inflammatory Bowel Disease: From Prevailing Clinical Evidence to Future Possibilities
    Hari K. Somineni et al, 2018, Clinical Gastroenterology and Hepatology CrossRef
  23. Management of Ulcerative Colitis in the Elderly
    Manish P. Shrestha et al, 2018, Drugs Aging CrossRef
  24. null
    Janett Nörenberg et al, 2019 CrossRef
  25. Secretion of Alpha-Hemolysin by Escherichia coli Disrupts Tight Junctions in Ulcerative Colitis Patients
    Hengameh Chloé Mirsepasi-Lauridsen et al, 2016, Clinical and Translational Gastroenterology CrossRef
  26. Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease
    Jessica Breton et al, 2019 CrossRef
  27. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review
    Dong Yeon Jeong et al, 2019, Autoimmunity Reviews CrossRef
  28. The microbiome, cancer, and cancer therapy
    Beth A. Helmink et al, 2019, Nat Med CrossRef
  29. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission
    Michelle G Rooks et al, 2014, ISME J CrossRef
  30. Acute severe ulcerative colitis: from pathophysiology to clinical management
    Pieter Hindryckx et al, 2016, Nat Rev Gastroenterol Hepatol CrossRef
  31. Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease
    Maebh Kelleher et al, 2019, Cytokine & Growth Factor Reviews CrossRef
  32. Dysregulation of Intestinal Epithelial Cell RIPK Pathways Promotes Chronic Inflammation in the IBD Gut
    Ricard Garcia-Carbonell et al, 2019, Front. Immunol. CrossRef
  33. Microbial biofilms and gastrointestinal diseases
    Erik C. von Rosenvinge et al, 2013, Pathogens Disease CrossRef
  34. null
    Chaorui Tian et al, 2013 CrossRef
  35. Ciprofloxacin Usage and Bacterial Resistance Patterns in Crohn’s Disease Patients With Abscesses
    Soo-Kyung Park et al, 2014, Journal of Clinical Gastroenterology CrossRef
  36. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases
    Marta Sobczak et al, 2014, Pharmacological Reports CrossRef
  37. Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigateFusobacterium varium?
    G. Fiorino et al, 2014, Aliment Pharmacol Ther CrossRef
  38. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report
    Dan Turner et al, 2014, Journal of Crohn's and Colitis CrossRef
  39. First Case Report of De Novo Ulcerative Colitis Developing After Orthotopic Liver Transplantation Successfully Treated by Granulocyte and Monocyte Apheresis
    S. Ihara et al, 2014, Transplantation Proceedings CrossRef
  40. Gut Microbiota and Inflammatory Bowel Disease: The Role of Antibiotics in Disease Management
    David H. Kerman et al, 2014, Postgraduate Medicine CrossRef
  41. Use of antibiotics in patients with Crohn's disease: A systematic review and meta-analysis
    Jie Wen Su et al, 2015, Journal of Digestive Diseases CrossRef
  42. Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches
    Jonathan J. Hansen et al, 2015, Curr Treat Options Gastro CrossRef
  43. A new therapeutic association to manage relapsing experimental colitis: Doxycycline plus Saccharomyces boulardii
    José Garrido-Mesa et al, 2015, Pharmacological Research CrossRef
  44. Controlled delivery of a new broad spectrum antibacterial agent against colitis: In vitro and in vivo performance
    M.S. Nieto-Bobadilla et al, 2015, European Journal of Pharmaceutics and Biopharmaceutics CrossRef
  45. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis
    V. Gupta et al, 2016, Aliment Pharmacol Ther CrossRef
  46. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases
    R. B. Sartor, 2016, Aliment Pharmacol Ther CrossRef
  47. Antibiotics as deep modulators of gut microbiota: between good and evil
    Gianluca Ianiro et al, 2016, Gut CrossRef
  48. null
    Ralph Francescone et al, 2016 CrossRef
  49. Advances in Gut Microbiome Research and Relevance to Pediatric Diseases
    Lindsey Albenberg et al, 2016, The Journal of Pediatrics CrossRef
  50. Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered
    Yu Qi Qiao et al, 2016, Journal of Digestive Diseases CrossRef
  51. Pediatric Inflammatory Bowel Disease
    Máire A. Conrad et al, 2017, Pediatric Clinics of North America CrossRef
  52. The role of the gut microbiota in the treatment of inflammatory bowel diseases
    Ioanna Aggeletopoulou et al, 2019, Microbial Pathogenesis CrossRef
  53. Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases
    Akihiko Oka et al, 2020, Dig Dis Sci CrossRef
  54. Host–microbiota interactions in inflammatory bowel disease
    Roberta Caruso et al, 2020, Nat Rev Immunol CrossRef
  55. null
    Klaus-Michael Keller, 2020 CrossRef
  56. Double‐blind, randomised, placebo‐controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn’s disease
    Scott D. Lee et al, 2020, GastroHep CrossRef
  57. IBDs and the pediatric age: Their peculiarities and the involvement of the microbiota
    Lucia Cococcioni et al, 2020, Digestive and Liver Disease CrossRef
  58. Effect of antibiotic therapy in patients with ulcerative colitis: a meta-analysis of randomized controlled trials
    Wenjie Xi et al, 2020, Scandinavian Journal of Gastroenterology CrossRef
  59. Impact of Microbial Metabolites on Microbiota–Gut–Brain Axis in Inflammatory Bowel Disease
    Davide Banfi et al, 2021, IJMS CrossRef
  60. null
    Samuel Bitton et al, 2021 CrossRef
  61. Modulation of the Gut Microbiota-farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice
    Mengque Xu et al, 2021 CrossRef
  62. null
    Legaki Evangelia et al, 2021 CrossRef
  63. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting
    Belinda De Simone et al, 2021, World J Emerg Surg CrossRef
  64. Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
    Anna Torun et al, 2021, Front. Immunol. CrossRef
  65. Antibiotics in pediatric Inflammatory Bowel Diseases: a systematic review
    Charlotte M. Verburgt et al, 2021, Expert Review of Gastroenterology & Hepatology CrossRef
  66. Outcomes of Immune Checkpoint Inhibitor–related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections
    Weijie Ma et al, 2021 CrossRef
  67. Micro- and nanotechnological delivery platforms for treatment of dysbiosis-related inflammatory bowel disease
    Dingpei Long et al, 2021, Nanomedicine CrossRef
  68. null
    Catiele Antunes et al, 2021 CrossRef
  69. Inflammatory bowel disease: The role of commensal microbiome in immune regulation
    Martín Ivan Wah-Suárez et al, 2021, Gastroenterología y Hepatología CrossRef
  70. Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome
    Yonghyun Lee et al, 2021, Advanced Drug Delivery Reviews CrossRef
  71. Naringin Exhibited Therapeutic Effects against DSS-Induced Mice Ulcerative Colitis in Intestinal Barrier–Dependent Manner
    Ruige Cao et al, 2021, Molecules CrossRef
  72. Emerging Pharmacotherapy for Inflammatory Bowel Diseases
    Hua Luo et al, 2022, Pharmacological Research CrossRef
  73. Identification of gut microbiome and transcriptome changes in ulcerative colitis and pouchitis
    Xin Gao et al, 2022, Scandinavian Journal of Gastroenterology CrossRef
  74. Abdominal Abscess in Crohn's Disease: Multidisciplinary Management
    E. Joline de Groof et al, 2014, Dig Dis CrossRef
  75. Gastrointestinal dysbiosis and Escherichia coli pathobionts in inflammatory bowel diseases.
    Andreas Munk Petersen, 2022, APMIS CrossRef
  76. The Role of the Human Gut Microbiome in Inflammatory Bowel Disease and Radiation Enteropathy
    Darren Fernandes et al, 2022, Microorganisms CrossRef
  77. A 7-Year-Old With Persistent Fever and Cough
    Ethan S. Vorel et al, 2022 CrossRef
  78. Inflammatory bowel disease: The role of commensal microbiome in immune regulation
    Martín Ivan Wah-Suárez et al, 2022, Gastroenterología y Hepatología (English Edition) CrossRef
  79. Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Koch’s postulates
    HanZheng Zhao et al, 2022, Front. Med. CrossRef
  80. Treatment of Crohn's disease
    Petr BARTOŠKA et al, 2022, Gazz Med Ital - Arch Sci Med CrossRef